» Articles » PMID: 39772271

Viral Oncogenesis: Synergistic Role of Genome Integration and Persistence

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2025 Jan 8
PMID 39772271
Authors
Affiliations
Soon will be listed here.
Abstract

Persistence is a strategy used by many viruses to evade eradication by the immune system, ensuring their permanence and transmission within the host and optimizing viral fitness. During persistence, viruses can trigger various phenomena, including target organ damage, mainly due to an inflammatory state induced by infection, as well as cell proliferation and/or immortalization. In addition to immune evasion and chronic inflammation, factors contributing to viral persistence include low-level viral replication, the accumulation of viral mutants, and, most importantly, maintenance of the viral genome and reliance on viral oncoprotein production. This review focuses on the process of genome integration, which may occur at different stages of infection (e.g., HBV), during the chronic phase of infection (e.g., HPV, EBV), or as an essential part of the viral life cycle, as seen in retroviruses (HIV, HTLV-1). It also explores the close relationship between integration, persistence, and oncogenesis. Several models have been proposed to describe the genome integration process, including non-homologous recombination, looping, and microhomology models. Integration can occur either randomly or at specific genomic sites, often leading to genome destabilization. In some cases, integration results in the loss of genomic regions or impairs the regulation of oncogene and/or oncosuppressor expression, contributing to tumor development.

References
1.
Sakakibara N, Mitra R, McBride A . The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J Virol. 2011; 85(17):8981-95. PMC: 3165833. DOI: 10.1128/JVI.00541-11. View

2.
Lewis P, Emerman M . Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 1994; 68(1):510-6. PMC: 236313. DOI: 10.1128/JVI.68.1.510-516.1994. View

3.
Sartorius K, An P, Winkler C, Chuturgoon A, Li X, Makarova J . The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation. Front Immunol. 2021; 12:661204. PMC: 8117219. DOI: 10.3389/fimmu.2021.661204. View

4.
Kannian P, Green P . Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis. Viruses. 2011; 2(9):2037-2077. PMC: 3185741. DOI: 10.3390/v2092037. View

5.
Agustiningsih A, Rasyak M, Turyadi , Jayanti S, Sukowati C . The oncogenic role of hepatitis B virus X gene in hepatocarcinogenesis: recent updates. Explor Target Antitumor Ther. 2024; 5(1):120-134. PMC: 10918233. DOI: 10.37349/etat.2024.00209. View